Contents

United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment

September 1, 2017

Clinical trial

United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment.

Hersh PS, Stulting RD, Muller D, Durrie DS, Rajpal RK.

Ophthalmology. 2017 Sep;124(9):1259-1270.
Full text | Metrics.

Main finding: Corneal collagen crosslinking was effective in improving the maximum keratometry value and visual acuity in eyes with progressive keratoconus at 1 year after treatment, with an excellent safety profile.

 

  • Purpose: To evaluate safety and efficacy of corneal crosslinking in progressive keratoconus
  • Study type: Randomized controlled trial
  • Condition: Keratoconus

Participants: Age ≥ 14yo, progressive keratoconus
-max K ≥47.0
-corrected distance VA <20/20

 

  • n=205 patients

 

Intervention:

 

Group 1: Standard CXL (epithelium removed, 0.1% riboflavin q2mins for 30mins, UV-A 3mW/cm2 for 30mins):
Group 2: Control (epithelium not removed, 0.1% riboflavin q2mins for 30mins)

Max K decreased by 1.6 dioptres in the treatment group vs continued progression in control group.

 

CDVA improved by 5.7 logMAR units, while UCVA improved 4.4 logMAR units.

 

Corneal haze was the most frequent adverse event

 

There was no significant change in endothelial cell count

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2024 - sourceshed